Oppenheimer analyst Hartaj Singh maintained a Hold rating on Gilead Sciences (NASDAQ: GILD) yesterday. The company’s shares closed yesterday at $73.97.
“Gilead (GILD) and partner Galapagos (GLPG) reported (9/11/18) positive FINCH 2 Phase 3 data in adults with moderate/severe rheumatoid arthritis (RA) and prior inadequate response to biologic agents. Efficacy results for filgotinib were broadly similar to previously reported studies for competing JAK-inhibitors upadacitnib (non- approved) and baricitinib (approved), but the limited safety data in the press release imply a cleaner safety profile. We believe the results are deceptively better than expected. The risk/benefit profile in FINCH 2 indicates that both doses of filgotinib could get approved, whereas the risk/benefit profile of upadacitnib implies (like baricitnib) that only the lower dose might get approved. We view FINCH 2 as a clear, albeit early, win for the JAK crown, but await greater visibility.”
According to TipRanks.com, Singh is a 4-star analyst with an average return of 9.5% and a 47.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $89.44, representing a 20.9% upside. In a report released yesterday, Robert W. Baird also reiterated a Hold rating on the stock with a $79 price target.
See today’s analyst top recommended stocks >>
Based on Gilead Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.69 billion and net profit of $1.82 billion. In comparison, last year the company earned revenue of $7.13 billion and had a net profit of $3.07 billion.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. Earlier this month, John C. Martin, a Director at GILD sold 50,000 shares for a total of $3,707,809.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.